

European RDI Support









# Agenda

- The Horizon Europe programme
- Cluster 1 of the Pillar 2 of Horizon Europe
  - Destinations and Health Topics 2024
- Health Partnerships: IHI
- EIT Health
- Luxinnovation Support






The Horizon Europe Programme



## Horizon Europe



### European Research & Innovation funding programme 2021-2027





**European Research Council** 

Marie Skłodowska-Curie Actions

**Research Infrastructures** 





**European Innovation Council** 

European innovation ecosystems

European Institute of Innovation and Technology

Widening Participation and Strengthening the European Research Area

Widening participation and spreading excellence

Reforming and Enhancing the European R&I system



**European Research Council** 

Marie Skłodowska-Curie Actions

- Bottom-up
- Any area
- Often lower TRL
- Often no consortia



- Thematic calls, predefined (top down)
- Consortia
- Mid high TRL



- Bottom-up
- Any area
- From low to high TRL
- Both consortia and individual companies

# Everyone can play a role






### Legal entities

**Public or private** 















What you get



What you bring

Expertise, networking, visibility

Innovative ideas, concepts, solutions

#### **Company**

New markets, networking, pilot

Manufacturing, products

#### Researcher

Valorisation

Cutting edge findings

# / support / NGO

Testing new solutions, codesign

End user access

#### City

Testing new solutions, co-design

Testbeds

#### **Public office**

Piloting, databased policy, valorisation

Data





# Projects



### Nature and Approach

#### Collaborative:

Consortia must be composed of at least three legal entities, established in different Member States or Associated States.

#### Individual:

a single institution submits and carries out the project.

#### Bottom-up (free subject):

"open" calls that accept projects from all technological fields or sectors of activity.

#### Top-down (compulsory subject):

calls that only accept projects that meet specific thematic or business sector criteria defined by the European Commission.



## Some basics!



### Funding instruments

PILLAR 2 Collab. projects

- Research and Innovation Actions (RIA): 100 % funding | test your solutions to develop a proof-of-concept, a prototype
- ✓ Innovation Action (IA): 70% funding (100% to public research) | bring your proof of concept closer to real life application
- Coordination and Support Actions (CSA): 100% funding | network with
   your colleagues on key policy issues

PILLAR 3


- EIC Accelerator: 70% funding + equity | scale up SMEs and start-ups
- EIT Health: collaborative projects and educational programmes



# Technological Readiness Level (TRL)



From research to innovation





# Collaborating at EU level



#### **Motivation**

#### Excellence:

Competitive programme proves applicant's maturity & skills

### Networking:

Work with relevant players in your field

#### Impact:

Address scientific & economic issues in trans-European partnerships

#### Funding:

Advantageous funding rates (100% of eligible costs + 25% overhead)

#### Market:

International consortia give visibility & credibility vis-à-vis investors & customers






### Pillar II: HEALTH







Impact-oriented: contribution to EU policy priorities

- Research & Innovation Activities
- Top down topics: propose your solution to the stated problem
- Collaborative projects (3+ partners)

<sup>\*</sup> The European Institute of Innovation & Technology (EIT) is not part of the Specific Programme






### HE STRUCTURE





### Consortia submit proposal at the topic level



## HE Pillar II: Health 2023-2024





- 2024 Health two-stage calls are currently open: <u>here</u>
- Commission Info Day on the 2024 topics <u>here</u>
- 2024 Health single-stage calls open on 26 October 2023

Destination 1 - Staying healthy in a rapidly changing society

Destination 2 - Living and working in a health-promoting environment

Destination 3 - Tackling diseases and reducing disease burden

Destination 4 - Ensuring access to innovative, sustainable and high-quality health care.

Destination 5 - Unlocking the full potential of new tools, technologies and digital solutions for a healthy society.

Destination 6 - Maintaining an innovative, sustainable and globally competitive health-related industry.





### D1: Staying healthy in a rapidly changing society



Citizens of all ages stay healthy and independent in a rapidly changing society thanks to healthier lifestyles and behaviours, healthier diets, healthier environments, improved evidence based health policies, and more effective solutions for health promotion and prevention

# **EXPECTD IMPACTS**

- Citizens adopt healthier lifestyles and behaviours, make healthier choices and maintain longer a healthy, independent and active life with a reduced disease burden, including at old ages or in other vulnerable stages of life.
- Citizens are able and empowered to manage better their own physical and mental health and well-being, monitor their health, and interact with their doctors and health care providers.
- Citizens' trust in knowledge-based health interventions and in guidance from health authorities is strengthened, including through improved health literacy (including at young ages), resulting in increased engagement in and adherence to effective strategies for health promotion, diseases prevention and treatment, including increased vaccination rates and patient safety.



### **Destination 1: Topics in 2024**

- HORIZON-HLTH-2024-STAYHLTH-01-02two stage
   Towards a holistic support to children and adolescents' health and care provisions in an increasingly digital society
- Opening: 30 March 2023
- Closure 1<sup>st</sup> Stage: 19 September 2023
- Closure 2<sup>nd</sup> Stage: 11 April 2024
- Instrument: RIA
- Tot: 30M€
- Project size: 8-10 M€

- HORIZON-HLTH-2024-STAYHLTH-01-05two-stage: Personalised prevention for non-communicable diseases - addressing areas of unmet needs using multiple data sources
- Opening: 30 March 2023
- Closure 1<sup>st</sup> Stage: 19 September 2023
- Closure 2<sup>nd</sup> Stage: 11 April 2024
- Instrument: RIA
- Tot: 50M€
- Project size: 8-12M€



## STAYHLTH 01 02 two stage: (RIA 8-10M)




Towards a holistic support to children and adolescents' health and care provisions in an increasingly digital society:

### **Expected outcomes**



- Children, adolescents and their parents/carers:
- **empowered in prevention strategies** to manage, maintain and improve their own health
- access and use person centred, widely available solutions for children and adolescents' health, care and wellbeing
- Children and adolescents monitor their health risks, adopt healthy lifestyles everywhere and interact with their doctors and carers.

### Scope (all)



- Advance person centred to support children and adolescents' health and care
- Develop and integrate innovative, privacy preserving tools to help children and adolescents lead healthy, active and social lifestyles, prevent diseases
- Empower children and adolescents to navigate the health and care systems
- Stimulate the adoption of person centred approaches and solutions for better health, care and wellbeing
- Develop and disseminate evidence based guidance and tools for children and adolescents



### D2: Living and working in a health Promoting environment

Filling knowledge gaps in the understanding of the impacts on our health and well-being of those environmental, occupational and socio-economic risk factors that have the most significant or widespread societal impacts

 Policy-makers and regulators are well informed about environmental, socioeconomic and occupational risk factors. Their policies are based on solid scientific evidence

# **EXPECTD IMPACTS**

- Determinants of disease are known, understood and reduced
- The health threats from hazardous chemicals and air, water and soil pollution and contamination is substantially reduced
- Living and working environments in European cities and regions are healthier
- The adaptive capacity and resilience of populations and health systems in the EU to climate and environmental change-related health risks is strengthened
- Citizens' health and well-being is protected and promoted





### **Destination 2: Topics in WP 2024**



 HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage: The role of environmental pollution in noncommunicable diseases: air, noise and light and hazardous waste pollution

Closure: 19.09.2023

Tot: 60M€

• Project size: 7-8M€



### D3: Tackling diseases and reducing disease burden



Develop new prevention measures, public health interventions, diagnostics, vaccines, therapies, antimicrobials and their alternatives, as well as to improve existing prevention strategies to create tangible impacts, taking into account sex/gender-related issues.

# **EXPECTD IMPACTS**

- Health burden of diseases in the EU and worldwide is reduced
- Premature mortality from NCDs is reduced by one third (by 2030), mental health and well being is promoted
- Health care systems benefit from strengthened research and innovation expertise
- Reduced (cross border) health threat of epidemics and AMR pathogens, in the EU. Combat epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases
- Patients and citizens empowered to make and shape decisions for their health, and better adhere to knowledge based disease management





# Destination 3: 6 topics in 2024 (5 RIAs and 1 CSA)

- HORIZON-HLTH-2024-DISEASE-03-08-two-stage: Comparative effectiveness research for healthcare interventions in areas of high public health need
- Closure 1<sup>st</sup> Stage: 19.09.2023
- Closure 2<sup>nd</sup> Stage:
   11.04.2024
- Instrument: RIA
- Budget: 45M€
- Project size: 6-7M€
- Blind evaluation pilot (1st Stage)
- Lump sum topic

- HORIZON-HLTH-2024-DISEASE-03-11-two-stage: Pandemic preparedness and response: Adaptive platform trials for pandemic preparedness
- Closure 1<sup>st</sup> Stage: 19.09.2023
- Closure 2<sup>nd</sup> Stage:
   11.04.2024
- Instrument: RIA
- Budget: 30M€
- Project size: 8-10M€
- Blind evaluation pilot (1st Stage)
- Lump sum topic

- HORIZON-HLTH-2024-DISEASE-03-13-two-stage: Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders
- Closure 1<sup>st</sup> Stage: 19.09.2023
- Closure 2<sup>nd</sup> Stage:
   11.04.2024
- Instrument: RIA
- Budget: 25M€
- Project size: 6-8M€
- Blind evaluation pilot (1st Stage)
- Lump sum topic









# Destination 3: 6 topics in 2024 (5 RIAs and 1 CSA)

- HORIZON-HLTH-2024-DISEASE-03-14-two-stage: Tackling high-burden for patients, under-researched medical conditions
- Closure 1<sup>st</sup> Stage: 19.09.2023
- Closure 2<sup>nd</sup> Stage:
   11.04.2024
- Instrument: RIA
- Budget: 25M€
- Project size: 6-7M€
- Blind evaluation pilot (1st Stage)
- Lump sum topic

- HORIZON-HLTH-2024-DISEASE-08-12: Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness
- Closure: 11.04.2024
- Instrument: CSA
- Budget: 2M€
- Project size: 2M€

- HORIZON-HLTH-2024-DISEASE-08-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential
- Closure: 11.04.2024
- Instrument: RIA
- Budget: 50M€
- Project size: 7-8M€

## Disease 03-13 two stage: (RIA 6-8M)



Validation of fluid derived biomarkers for the prediction and prevention of brain disorders: fluid-derived tests for markers for early signs of the disorder, and which can be deployed for widespread clinical use are needed.

### **Expected outcomes**



- SoA info, data, tools, and best practices to develop diagnostics for effective therapeutics and/or preventive strategies.
- Better understanding of mechanisms underlying brain disorders.
- New open db and/or integration for storage and sharing of collected data.
- Health professionals use biomarker tests for early detection. Stakeholders aware.
- Engagement of patients and caregivers

### Scope (all)



- Validate biomarkers for early stages Brain disorders (mental, AD &PD, etc), acceptance, guide treatment
- Exploit existing data and cohorts and generate new data. Sharing of samples, using infrastructures
- Inclusion patients and oragnisation
- Gender dimension
- Demonstrate cost gain in the management of diseases
- SME participation



# D4: Ensuring access to innovative, sustainable and high quality health care



# Health systems need to become more effective, efficient, accessible, sustainable and resilient.

# **EXPECTD IMPACTS**

- Equal access to innovative, sustainable and high quality health care
- Resilient and sustainable health care services and systems with emphasis on health promotion and disease prevention enable shifting from hospital centred to community based, people centred and integrated health care structures
- Health care providers are equipped with skills and competences suited for future needs and health care systems are modernized
- Citizens are empowered in their own health management informal carers are supported and specific needs of more vulnerable groups are addressed





## **Destination 4: Topics in 2024**

- HORIZON-HLTH-2024-CARE-04-04two-stage:
- Access to health and care services for people in vulnerable situations
- Closure: 19 Sep 2023 (First Stage) 11
   Apr 2024 (Second Stage)
- Instrument: RIA
- Tot: 30M€
- Project size: 4-6M€





# D5: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

• Europe's scientific and technological expertise and know how, its capabilities for innovation in new tools, technologies and digital solutions, and its ability to take up, scale up and integrate innovation in health care is world class.

# **EXPECTD IMPACTS**

- Citizens benefit from targeted and faster research resulting in safer, sustainable, efficient, cost effective and affordable tools, technologies and digital solutions.
- The EU gains high visibility and leadership in health technology development.
- Integration of innovative diagnostic, therapeutic and digital approaches for people centred health care solutions.
- Health research and innovation, quality and outcome of health care is improved.
- Citizens trust and support innovative technologies for health care.





### **Destination 5: Topics in 2024**

 HORIZON-HLTH-2024-TOOL-05-06-twostage:

Innovative non-animal human-based tools and strategies for biomedical research

Closure of Stage 1: 19 Sept. 2023

Closure of Stage 2: 11 Apr. 2024

Instrument: RIA

Tot: 25M€

Project size: 4-8M€

HORIZON-HLTH-2024-TOOL-11-02:
 Bio-printing of living cells for regenerative medicine

Closure: 11 April 2024

Instrument: RIA

Tot: 25M€

Project size: 6-8M€



### TOOL-05-06-two-stage (RIA 4-8M)



# Innovative non-animal human-based tools and strategies for biomedical research

### **Expected outcomes**



- Tools and strategies more relevant to the human situation vs current used animal models
- Fewer live animals used in biomedical research;
- Improved human relevant tools or strategies allowing for a faster pace of innovation;
- Legislators and regulators: EU leadership in non animal based biomedical research
- Healthcare providers and patients: innovative tools or strategies enabling improved disease prediction, prevention and treatment.

### Scope (all)



- technologies and methodological approaches such as omics and other high throughput procedures, human derived cell based material, organoids, micro physiological systems, and in silico models;
- advance the SoA in areas of biomedical research;
- knowledge sharing, uptake, or translation into health policies
- Harm, cost benefit assessment, ease of production vs current practices should also be considered
- Model qualification and standardisation to demonstrate their translational values







# D6: Maintaining an innovative, sustainable and globally competitive health industry

# **EXPECTD IMPACTS**

- Health industry (including SMEs) is more competitive and sustainable, assuring EU leadership and strategic autonomy in medical supplies and digital technologies.
- Health industry is working more efficiently along the value chain.
- European standards ensuring safety and quality of healthcare, as well as
  effectiveness and interoperability of health innovations.
- Swift uptake of innovative health technologies and services.
- Reliable and timely access to key manufacturing capacity.





### Destination 6: Topics in 2024 – Single stage

HORIZON-HLTH-2024-IND-06-08:
 Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)

Closure: 11 April 2024

Instrument: RIA

• Total: 10M€

Project size: 8-10M€

HORIZON-HLTH-2024-IND-06-09:
 Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators

Closure: 11 April 2024

Instrument: CSA

Total: 2M€

Project size: 2M€



### HE Pillar II: Health 2023-2024





### Timelines for calls (WP 2023-2024, Topics/Calls in 2024)

- Opening of calls:
  - ➤ single-stage calls: 26 October 2023
  - two-stage calls 1st stage: 30 March 2023
- Closure of calls (deadlines)
  - ➤ single-stage calls: 11 April 2024
  - ➤ two-stage calls 1st stage: 19 September 2023 / 2nd stage: 11 April 2024





# Partnerships





### HEALTH PARTNERSHIPS in HE





# Institutional Partnerships



IHI

European Partnership for Innovative Health (2021)



**GHP-EDCTP3** 

Global Health Partnership (2021)

#### **Co-funded Partnerships**



**ERA4Health** 

European Research and Innovation Area for Health (2022)



PM

European Partnership for Personalised Medicine (2023)



**PARC** 

European Partnership for Chemicals Risk Assessment (2021)



RD

European Partnership on Rare Diseases (2023)



**THCS** 

European Partnership on Health and Care Systems Transformation (2022)



**AMR** 

European Partnership for One Health/AMR Antimicrobial Resistance (2023-24)

# Co-Programmed Partnerships



European Pandemic Preparedness Partnership





### Innovative Health Initiative (IHI)







#### The Innovative Health Initiative

- Budget over 7 years
  - €1.2 billion EU funding from EC
  - €1.2 billion contribution from industry and contributing partners
- Institutional partnership with the EU (Joint Undertaking)
- Cross sectoral between
  - Pharmaceutical and biotech sector (EFPIA, Vaccines Europe, EuropaBio)
  - medical technologies sector (MedTech Europe, COCIR)













## Innovative Health Initiative (IHI)



#### **SPECIFIC OBJECTIVES**

- 1. Determinants of health and priority disease areas
- **2. Bringing together health industry sectors** and other stakeholders to develop tools, data, platforms, etc. for improved prediction, prevention, interception, diagnosis, treatment and management of diseases
- 3. Demonstrate the feasibility of people-centred, integrated healthcare solutions
- 4. Potential of digitalisation and data exchange in healthcare
- 5. New and improved evaluation methodologies and models for a comprehensive assessment of integrated healthcare solutions




### Innovative Health Initiative (IHI)

#MakingInnovationHappen





## How does IHI work? two-stage procedure







### Innovative Health Initiative (IHI)





# How does IHI work? single-stage procedure









## IHI Calls 4 and 5



#### IHI call 4 (two-stage call)

- Expanding translational knowledge in minipigs: a path to reduce and replace non-human primates in nonclinical safety assessment
- <u>Patient-centric blood sample collection to enable decentralised clinical trials and improve access to healthcare</u>
- <u>Inclusive clinical studies for equitable access to clinical research in Europe</u>
- <u>Establishing novel approaches to improve clinical trials for rare and ultra-rare diseases</u>
- Safe & sustainable by design (SSbD) packaging and single use device solutions for healthcare products
- <u>Sustainable circular development and manufacturing of healthcare products and their quantitative environmental impact assessment</u>

#### IHI call 5 (single-stage call)

- Accelerating the implementation of new approach methodologies and other innovative non-animal approaches for the development, testing and production of health technologies
- <u>Development and proof of principle of new clinical applications of theranostics solutions</u>
- Improved prediction, detection, and treatment approaches for comprehensive stroke management
- Maximising the potential of synthetic data generation in healthcare applications




### **IHI Call Days**





### INFO SESSIONS ON ALL TOPICS OF CALLS AND 4 and 5



#### **PROJECT OFFERS**

Synthetic data (SD) can help to overcome data privacy challenges, associated data-sharing limitations, and data scarcity in healthcare. Despite the high potential, there is limited trust and hence the use of SD in healthcare as well as in other industries. We propose to create trust in SD by developing an SD assurance scheme - a systematic approach that involves a set of procedures and standards designed to instill confidence by ensuring that both the SD generation process and resulting SD meet specific requirements and expectations.

DNV has a vast experience in risk management and quality assurance. DNV's expertise in standards and assurance can provide robust frameworks to guide the development and evaluation of SD. In the healthcare sector, DNV has a profound understanding of the regulatory landscape and a history of collaboration with healthcare research institutions. Furthermore, DNV has an ongoing industrial Ph.D. project in collaboration with Oslo University and Oslo University Hospital on the use of SD for the validation of AI-based tools in healthcare.

DNV does not qualify for funding through IHI; therefore, we will cover our time via in-kind contribution.







# Pillar 3: EIT Health






### EIT HEALTH



- Build an ecosystem where fresh thinking in healthcare can thrive.
  - It connects world-class organisations across Europe from the three worlds of business, research and education.

### Knowledge Triangle:

• to connect the brightest minds in business, research and education. We believe the best innovation happens when these three worlds meet.





### EIT HEALTH PROGRAMMES





#### **Business Creation**

- Bootcamps
- Mentoring&Coaching Network
- Wild Card
- Catapult
- Finance Booster
- Open Innovation
- Gold Track
- Bridgehead
- Venture Centre of Excellence

#### Education

- Winter/Summer Schools
- Fellowship Programme
- Training Modules

#### Innovation

- Partner-driven
- Start-up driven
- Fast-track (DiGinnovation)

- Call for Education and Innovation projects expect to open later this year
- Call for Business Creation applications opens in Q1 2024
- Business Creation programmes in **bold** open for applications throughout the year



### EIT HEALTH PROGRAMMES





	Programme	Proposal Requirements	Funding	Selection rate
	Education	<ul> <li>Topics linked to the Flagships</li> <li>At least 2 entities</li> <li>Any organisation can apply</li> <li>Involve partners from EIT Health and RIS in the consortium, including non- academic</li> </ul>	<ul> <li>Up to €200k</li> <li>70% funding</li> </ul>	Between 10% and 50%, depends on the programme
	Innovation	<ul> <li>Topics linked to the Flagships, TRL5+</li> <li>At least 2 entities</li> <li>Led by EIT Health partner or start-up</li> <li>50% EIT Health partners in consortium</li> </ul>	<ul> <li>Up to €2million</li> <li>70% funding</li> <li>Financial return to EIT Health</li> </ul>	1-3 proposals per cut-off



# EIT Health examples



Education and training activities with demonstrable outcomes. Examples:

- AIProHealth: How Artificial Intelligence (AI) can support healthcare
  - Fundamentals of AI and its use in healthcare-based use-cases.
  - Requirements and impact of implementation of AI in a clinical environment.
  - Evaluate the challenges and risks of AI in Healthcare and its use in a practical and meaningful way.
- Dementia Inclusive Hospitals from a Universal Design Approach
  - Massive Open Online Course (MOOC) focusing on dementia-friendly hospital design





Other EU Programmes

EU4Health




### EU4Health





### **Evolving budget and objectives**



#### Improve & foster Health

- Health promotion and prevention; cancer
- Protect People
  - preparedness
- Access to medicinal and medical devices
  - Enhance availability and affordability
- Strengthen Health System:
  - Health data, legislation, access to healthcare



### EU4Health





Grant based on actual costs declared with unit costs and flat rate elements

Grant = <u>partial</u> <u>reimbursement</u> of eligible costs that are incurred by beneficiaries and affiliated entities listed in the grant agreement at the fixed reimbursement rate.

- Reimbursement rate under the EU4Health programme 60% of eligible costs
- Reimbursement rate with exceptional utility: 80% of eligible costs

#### **Direct Costs**

- A. Direct personnel costs (employees + natural persons with direct contract + seconded persons)
- B. Subcontracting (engagement of a 3<sup>rd</sup> party to carry out certain activities of the proposed action)
- C. Purchase costs
  - a. Travel, accommodation and subsistence allowances (unit cost)
  - Equipment (depreciation, renting, leasing)
  - c. Other goods and services

#### **Indirect Costs**

E. Flat rate of 7% of total direct costs





### EU4Health WP 2024: 11 topics



- EU4H-2023-PJ-01: Supporting access to medical devices for cross border health threats (HERA)
- EU4H-2023-PJ-02: Supporting stakeholders on the prevention of NCDs in the area of chronic respiratory diseases
- EU4H-2023-PJ-03: <u>Preventing NCDs in the area of mental health including actions supporting vulnerable population groups, such as migrants, refugees, Roma people and displaced people from Ukraine</u>
- EU4H-2023-PJ-04: Preventing NCDs in the area of dementia and other neurological disorders
- EU4H-2023-PJ-05: Supporting the implementation of the strategic agenda for medical ionising radiation applications (SAMIRA)
- Action grants on mental health challenges for cancer patients and survivors:
  - EU4H-2023-PJ-06: Sub-topic (a): Mental health and Cancer
  - EU4H-2023-PJ-07: <u>Sub-topic (b): European Code for Mental Health</u>
- Action grants on the safety and quality of new Substances of Human Origin (Breast milk, faecal microbiota transplants)
  - EU4H-2023-PJ-08: <u>Sub-topic (a): Breast milk</u>
  - EU4H-2023-PJ-09 : <u>Sub-topic (b): Faecal microbiotic transplants</u>
- EU4H-2023-PJ-10: Action grants on Facilitating Organ Paired Exchange
- EU4H-2023-PJ-11: <u>Program on orphan medical devices, in particular targeting paediatric patients</u>
- EU4H-2023-PJ-12: Action grants to contribute to the organisations of conference and events



# DP-g-23-33-02: dementia and other neurological disorders

### Prevention and care of dementia and other neurological disorders

- Implementation public health policies
- Development best practices and public health guidelines
- Preparation and roll-out of innovative approaches
- Projects supporting patient pathways and targeting the prevention or care



Budget €1 million

#### **Proposal must include:**



- Measures to reduce health inequalities
- Vulnerable groups (migrants/refugees, people living under war conditions, disadvantaged children and women, LGBTQI, Roma, people with disabilities etc.)

#### **Expected results:**



- Initiatives to complement Member States' efforts
- Best practices, public health guidelines, patient pathways, new policy approaches, pilot testing of innovative approaches, training, health awareness and health literacy.

#### **Expected impact:**

Support Member States to reduce burden of NCDs, in particular dementia & other neurological disorders, and to reach SDGs, in particular Goal 3, target 3.4

The deadline: 17 October 2023, 17:00 (CET)






# EUROPEAN RDI Support Team



# European RDI Support Team

### National Contact Point for Horizon Europe



Understand your research focus and priorities

**Training and workshops (public or tailor-made)** 

- Monitor European RDI policies and agendas
- Identify and suggest most relevant funding opportunities

- Concept validation of EU RDI projects
- Search for partners and consortia

Support and monitor grant applications

Legal and financial support



# European RDI Support Team

### Ask for advice:

- From your NCPs
- From your institution support services
- From more experienced colleagues
- There are also specialised consultancies
- Start early, plan in advance

You can have a gradual approach, taking more responsibility with more experience: there is time to coordinate!





# Take away



### Horizon Europe NCP in Luxembourg - Personalised support

#### 1: SUPPORT

We are here to support your research

#### 2: TRAININGS

Luxinnovation proposal writing workshop

#### 3: BUILD YOUR PROPOSAL

Call identification, partner search, critical review, advising on legal and financial issues

Visit: horizoneurope.lu & Inscribe to our newsletter





### Other links



- Briefing to evaluators: <a href="https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/experts/standard-briefing-slides-for-experts\_he\_en.pdf">https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/experts/standard-briefing-slides-for-experts\_he\_en.pdf</a>
- Standard evaluation form: <a href="https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef\_he-ria-ia\_en.pdf">https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef\_he-ria-ia\_en.pdf</a>
- Become an expert: <a href="https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert">https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert</a>





# Thank you!

#### European RDI Support team

Francesca BorrelliNCP LuxembourgHealth Cluster

M (+352) 621 356 549 francesca.borrelli@luxinnovation.lu

#### **LUXINNOVATION GIE**

5, avenue des Hauts-Fourneaux L-4362 Esch-sur-Alzette

- www.luxinnovation.lu
- **in** Luxinnovation
- @Luxinnovation @LuxTradeInvest
- @Luxinnovation @LuxTradeInvest

